Blog

Radiologic assessment before first line therapy for mccRCC

Rashad Nawfal/X

Aug 1, 2024, 06:56

Radiologic assessment before first line therapy for mccRCC

Cancer Network shared a post on X:

”Radiological tumor burden, if shown to have a good prognostic role be easily calculable, could be used in pre-first-line immunotherapy assessment in metastatic clear cell renal cell carcinoma.”

Toni Choueiri shared a post by Cancer Network on X, adding:

”Congratulations super star Rashad Nawfal on his work regarding radiologic burden in mRCC!”

Read further.
Source: Cancer Network/X and Toni Choueiri/X

Rashad Nawfal is a Postdoctoral Research Fellow at the Dana-Farber Cancer Institute and Harvard Medical School. He is the Senior Advisor at Lebanese Oncology Interest Group (LOIG). Previously he was a Research Assistant at the American University of Beirut.

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).

He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA.

Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.